Introduction to Haemonetics Corporation

Haemonetics Corporation stands as a pioneering force in the global healthcare and medical technology industry, specializing in blood management, plasma collection, and surgical blood salvage solutions. Headquartered in Boston, Massachusetts, the company has built a reputation for engineering life-saving technologies that support hospitals, blood banks, plasma centers, and healthcare providers across more than 100 countries. With over 50 years of operational excellence, Haemonetics Corporation has consistently demonstrated its commitment to advancing medical science by improving the safety, efficiency, and availability of blood and plasma products. The company’s comprehensive portfolio includes automated blood collection systems, transfusion management software, and hemostasis management devices, all designed to address critical challenges in transfusion medicine and patient care.

As a top-tier Healthcare company, Haemonetics Corporation serves as a strategic partner for organizations seeking to optimize clinical workflows, reduce costs, and enhance patient outcomes. The company’s market reputation is built on a foundation of rigorous quality standards, regulatory compliance, and continuous innovation. Healthcare institutions, including major academic medical centers, community hospitals, and independent blood centers, rely on Haemonetics solutions to ensure the availability of safe blood products while minimizing waste and operational inefficiencies. The company’s global footprint, with manufacturing facilities in the United States, Europe, and Asia, underscores its ability to scale solutions for diverse healthcare systems. By integrating advanced data analytics and automation into its products, Haemonetics Corporation has positioned itself at the forefront of the digital transformation in healthcare, enabling real-time decision-making and improved clinical outcomes.

The company’s enduring success is driven by a deep understanding of the complex interplay between donor health, patient safety, and operational efficiency. Haemonetics Corporation invests heavily in research and development, with a focus on creating next-generation technologies that address emerging healthcare challenges, such as the growing demand for plasma-derived therapies and the need for precision medicine in transfusion. Through strategic acquisitions and partnerships, the company has expanded its capabilities into adjacent areas like hemostasis monitoring and blood management software, further solidifying its leadership in the healthcare technology ecosystem. This comprehensive profile introduces the company’s mission, history, and value proposition, setting the stage for a detailed exploration of what makes Haemonetics Corporation a premier employer and business partner in the healthcare industry.

Company History and Business Evolution

Haemonetics Corporation was founded in 1971 by Dr. John G. (Jack) G. and a team of medical innovators who recognized the need for safer, more efficient blood collection and processing methods. The company’s earliest breakthrough came with the development of the Cell Saver® system, a revolutionary device that enabled intraoperative blood salvage, reducing the need for allogeneic blood transfusions and conserving precious blood resources. During the 1970s and 1980s, Haemonetics expanded its product line to include automated plasma collection systems, such as the PCS2™, which became the gold standard for plasmapheresis. This period also saw the company establish a strong international presence, opening subsidiaries in Europe and Asia to meet growing global demand for blood management solutions.

The 1990s marked a transformative era for Haemonetics Corporation as it embraced digital technologies and software-driven solutions. The launch of the Haemonetics Blood Management System (BMS) integrated data analytics into transfusion workflows, enabling hospitals to track blood usage, reduce wastage, and improve patient outcomes. The company also ventured into hemostasis management with the acquisition of Medtronic’s blood management business in 2011, adding products like the Thrombelastograph® (TEG® 5000) to its portfolio. This acquisition positioned Haemonetics as a comprehensive provider of both blood collection and hemostasis monitoring solutions. In 2015, the company acquired Pall Corporation’s blood collection, filtration, and processing business, further strengthening its position in plasma collection and blood component separation.

The 2020s have been defined by a strategic pivot toward digital health and value-based care. Haemonetics launched the OneView™ data platform, which leverages artificial intelligence and machine learning to optimize inventory management and predict demand for blood products. The company also expanded its plasma collection capabilities with the NexSys PCS® system, featuring enhanced donor safety and operational efficiency. Recent milestones include the acquisition of Cardiovascular Systems, Inc. (CSI) in 2022, which added a line of vascular intervention devices, and the establishment of a dedicated innovation center in Silicon Valley to accelerate technology development. Today, Haemonetics Corporation serves over 5,000 hospitals and 2,000 plasma centers worldwide, with annual revenue exceeding $1.2 billion. The company’s evolution from a single-product startup to a diversified medical technology leader reflects its resilience, adaptability, and unwavering commitment to saving lives through innovation.

Haemonetics Corporation at a Glance

• Headquarters: Boston, Massachusetts, USA
• Founded: 1971
• CEO: Chris Lindop
• Annual Revenue: Approximately $1.2 billion (FY2024)
• Employees: Over 8,000 globally
• Stock Symbol: HAE (New York Stock Exchange)
• Key Products: Cell Saver®, PCS2™, NexSys PCS®, TEG® 5000, OneView™ platform
• Global Presence: Operations in 30+ countries, products sold in 100+ countries
• Industry Focus: Blood management, plasma collection, hemostasis monitoring, surgical blood salvage
• Manufacturing Locations: Boston, MA; San Juan, Puerto Rico; Tijuana, Mexico; Shenzhen, China; Hamburg, Germany
• Regulatory Certifications: ISO 13485, FDA, CE Mark, MDSAP
• Major Acquisitions: Medtronic Blood Management (2011), Pall Blood Collection (2015), CSI (2022)
• Innovation Centers: Boston (HQ), Silicon Valley, Bangalore, India
• Corporate Partnerships: American Red Cross, Blood Centers of America, HCA Healthcare, Mayo Clinic
• Patient Impact: Products used in over 30 million procedures annually
• Core Technology: Automated apheresis, transfusion informatics, viscoelastic hemostasis testing
• R&D Investment: Approximately 8% of annual revenue
• Employee Diversity: Women make up 42% of workforce, 35% of leadership roles
• Awards: Forbes America’s Best Employers, MedTech Breakthrough Awards, Frost & Sullivan Product Leadership
• Sustainability Goals: Carbon neutrality by 2040, zero waste to landfill by 2025

Mission, Vision, and Core Corporate Values

Haemonetics Corporation’s mission is to save lives and improve patient outcomes by providing innovative blood management and medical technology solutions that enhance the safety, efficiency, and quality of care. The company envisions a world where every patient has access to safe blood products and advanced therapies, and where healthcare providers can deliver precision medicine through integrated data insights. This vision is underpinned by four core corporate values: Patient First, Innovation, Integrity, and Collaboration. The “Patient First” value ensures that all business decisions prioritize patient well-being, from product design to customer support. “Innovation” drives the company’s commitment to continuous improvement and technological breakthroughs, such as AI-powered blood inventory management. “Integrity” is reflected in the company’s unwavering adherence to ethical standards, regulatory compliance, and transparent reporting. “Collaboration” fosters a culture of teamwork across departments, geographies, and partner organizations, enabling Haemonetics to solve complex healthcare challenges collectively.

These values are embedded in every aspect of the corporate culture, from employee performance evaluations to supplier partnerships. Haemonetics Corporation also emphasizes diversity, equity, and inclusion (DEI) as part of its core identity, recognizing that diverse perspectives fuel innovation and better serve global communities. The company has established employee resource groups (ERGs) for women, people of color, LGBTQ+ employees, and veterans, and it publishes annual DEI reports to track progress. Additionally, the company’s mission extends to sustainability, with goals to reduce carbon emissions, minimize waste, and promote ethical sourcing. By aligning its operations with the United Nations Sustainable Development Goals (SDGs), Haemonetics demonstrates a holistic commitment to responsible corporate citizenship.

Business Strategy and Future Roadmap

Haemonetics Corporation’s business strategy is centered on three growth pillars: expanding its core blood management franchise, accelerating innovation in plasma collection and hemostasis, and leveraging data analytics to create a connected ecosystem. The company plans to achieve these goals through a combination of organic innovation, strategic acquisitions, and geographic expansion. In the near term, Haemonetics is investing heavily in its OneView™ platform, which aims to become the industry standard for blood inventory optimization across hospital networks. The platform integrates electronic health records (EHRs), laboratory information systems, and supply chain data to provide real-time visibility into blood product usage and availability. This digital transformation is expected to reduce blood wastage by up to 30% and improve transfusion turnaround times, driving significant cost savings for healthcare customers.

Looking ahead, the company’s roadmap includes entering new therapeutic areas such as cell and gene therapy, where its expertise in apheresis and plasma collection can be applied to harvest stem cells and plasma for advanced treatments. Haemonetics has already piloted a system for collecting peripheral blood stem cells (PBSCs) and plans to scale this offering by 2026. In parallel, the company is expanding its presence in emerging markets, particularly in Asia-Pacific and Latin America, where rising healthcare expenditures and growing demand for plasma-derived medications are creating new opportunities. To support this expansion, Haemonetics is establishing regional manufacturing hubs and training centers to ensure local service capabilities. The company also intends to double its R&D spending in the next three years, focusing on software as a medical device (SaMD) and AI-driven clinical decision support tools. By 2028, Haemonetics aims to achieve $2 billion in annual revenue, driven by a diversified portfolio of consumables, devices, and digital services.

Products, Technologies, and Services

Haemonetics Corporation offers a comprehensive suite of products and services designed to address every stage of the blood lifecycle, from donor to patient. The product portfolio is structured into three core categories: Blood Collection, Blood Management, and Hemostasis Management. Under blood collection, the company provides automated apheresis systems such as the PCS2™ and NexSys PCS® for plasma collection, the MCS+® 9000 for platelet and red cell collection, and the Cell Saver® Elite® for intraoperative blood salvage. These systems incorporate proprietary Latham-Bowen™ centrifuge technology, which separates whole blood components with high yield and purity while minimizing donor discomfort. For blood management, Haemonetics offers the OneView™ platform, a cloud-based software that provides analytics for transfusion utilization, inventory management, and cost reduction. The company’s hemostasis management line includes the TEG® 5000 and TEG® 6s thromboelastography analyzers, which assess clotting function in real time to guide transfusion therapy and reduce bleeding complications.

In addition to hardware and software, Haemonetics provides professional services including clinical education, process optimization consulting, and technical support. The company’s Clinical Excellence Team offers on-site training for clinicians on blood conservation protocols, while its Business Intelligence Group helps hospitals benchmark their blood management performance against national standards. Haemonetics also operates a global service network with 24/7 support for equipment maintenance and troubleshooting. Recent technological innovations include the integration of machine learning algorithms into the OneView platform to predict future blood product demand based on historical usage patterns and scheduled surgeries. The company has also developed a mobile app for donors that enables real-time tracking of donations and rewards for loyalty, improving donor retention rates. With a strong focus on interoperability, all Haemonetics devices and software are designed to integrate with major EHR systems like Epic and Cerner, ensuring seamless data flow within healthcare IT ecosystems.

Industries and Markets Served

Haemonetics Corporation serves a diverse array of industries and markets within the healthcare sector, primarily focusing on hospitals, blood banks, plasma collection centers, and surgical centers. Within hospitals, the company’s solutions are deployed in surgical suites, intensive care units (ICUs), emergency departments, and transfusion services. Academic medical centers and teaching hospitals are major customers due to their high-volume surgical programs and research collaborations. Blood banks, including regional blood centers and national organizations like the American Red Cross, utilize Haemonetics equipment for automated component separation and storage. Plasma collection centers—both for-profit (e.g., CSL Plasma, Grifols) and non-profit—rely on the company’s apheresis systems to source plasma for fractionation into lifesaving therapies such as albumin, immunoglobulins, and clotting factors. Additionally, military and disaster relief organizations use Haemonetics portable blood salvage devices in field hospitals and combat zones to treat trauma patients with limited blood supplies.

The company also serves specialty surgical markets, including cardiac, orthopedic, and trauma surgery, where the Cell Saver system is widely adopted to reduce allogeneic blood transfusion requirements. In the emerging cell therapy market, Haemonetics is positioning its apheresis platforms for the collection of peripheral blood mononuclear cells (PBMCs) used in CAR-T cell therapies and regenerative medicine. The company’s market reach extends to veterinary medicine, where its blood salvage systems are used in animal hospitals for critical surgeries. Geographically, North America accounts for the largest share of revenue (approximately 60%), followed by Europe (25%), and Asia-Pacific (15%). Haemonetics continues to invest in expanding its presence in China and India, where rising healthcare infrastructure and government initiatives to improve blood safety are driving demand. The company also serves government and public health agencies through contracts for blood collection during emergencies, such as pandemics or natural disasters.

Leadership and Management Philosophy

The leadership team at Haemonetics Corporation is headed by Chris Lindop, who became CEO in 2020. Lindop brings a wealth of experience from previous roles at Becton Dickinson (BD) and General Electric Healthcare, where he led global medical device businesses. He is known for a people-centric and data-driven management style, emphasizing transparency, accountability, and continuous learning. The executive team includes leaders with deep expertise in R&D, operations, regulatory affairs, and commercial strategy, such as Dr. Sarah L. Larson (Chief Medical Officer), Michael J. F. (Mick) O’Brien (EVP of Global Operations), and Katherine A. (Katie) Brennan (Chief Commercial Officer). Haemonetics embraces a flat organizational structure to encourage cross-functional collaboration and rapid decision-making. The company’s management philosophy is grounded in servant leadership, where executives actively mentor emerging leaders and invest in employee development through programs like the Haemonetics Leadership Academy.

Underpinning this philosophy is a commitment to psychological safety and innovation. Leaders encourage calculated risk-taking and reward employees who challenge conventional thinking to improve patient outcomes. The company also prioritizes ethical leadership, with a strong compliance culture that includes annual training on anti-corruption, data privacy, and confidentiality. Haemonetics’ board of directors includes independent members from diverse backgrounds, including clinicians, technology entrepreneurs, and sustainability advocates, ensuring balanced oversight. The company regularly conducts employee engagement surveys and uses the results to refine leadership strategies, with a focus on fostering a sense of belonging and purpose. In 2023, over 85% of employees reported feeling valued and aligned with the company’s mission, reflecting the effectiveness of its management approach.

Corporate Events, Conferences, and Community Engagement

Haemonetics Corporation actively participates in major industry conferences and events to showcase its innovations and engage with the healthcare community. The company is a regular exhibitor and sponsor at: AABB (Association for the Advancement of Blood & Biotherapies) Annual Meeting, ISBT (International Society of Blood Transfusion) Congress, ASH (American Society of Hematology) Annual Meeting, and HFMA (Healthcare Financial Management Association) Annual Conference. At these events, Haemonetics presents clinical data, product demonstrations, and thought leadership sessions on topics such as blood conservation best practices and the economic impact of transfusion management. The company also hosts its own annual customer symposium, where users of its technologies share case studies and network with peers. These gatherings serve as a platform for gathering customer feedback and co-creating future product roadmaps.

Beyond conferences, Haemonetics is committed to community engagement through its Global Giving Program, which donates equipment and training to underserved regions. For example, the company has partnered with Project HOPE to provide Cell Saver systems to hospitals in sub-Saharan Africa, where blood shortages are critical. Employee volunteerism is encouraged through paid time off for community service, and the company matches employee donations to eligible charities. Haemonetics also hosts educational webinars and workshops for clinicians on topics like transfusion indicator management and hemostatic resuscitation. During the COVID-19 pandemic, the company launched a plasma donor loyalty program and supported vaccine distribution efforts at plasma centers. These initiatives underscore the company’s belief that corporate success is intertwined with the health of the communities it serves.

Employees and Workplace Culture

Haemonetics Corporation fosters a culture of inclusion, innovation, and well-being that attracts top talent from around the world. The global workforce of over 8,000 employees includes engineers, software developers, regulatory specialists, sales professionals, and manufacturing technicians. The company’s headquarters in Boston houses a state-of-the-art innovation lab and an open‑plan environment designed to encourage spontaneous collaboration. Flexible work arrangements, including remote and hybrid options, are offered for eligible roles to support work‑life balance. Employee benefits are comprehensive: health and wellness programs, generous parental leave, tuition reimbursement, and a 401(k) with company match. Haemonetics also provides mental health resources through an employee assistance program and access to meditation apps.

Career development is a priority, with internal mobility encouraged through a Job Rotation Program and an annual Talent Review that identifies high-potential employees for leadership tracks. The company’s Haemonetics University offers on‑demand training in technical skills, compliance, and project management. Employee resource groups (ERGs) for Women in Technology, Black Professionals, and Pride@Haemonetics foster a sense of belonging and provide networking opportunities. Annual employee satisfaction surveys (via Glint) track engagement levels, and results have improved steadily over the past three years. The company’s culture is summed up by the motto “One Haemonetics, One Mission”, which reinforces collective accountability for patient outcomes. This focus on employee well-being and professional growth has earned Haemonetics recognition as a “Best Place to Work” in multiple regions.

Job Details & Requirements for this Posting (Detailed)

Role: Senior Product Manager (Blood Management Solutions)

We are seeking a visionary Senior Product Manager to lead the strategic direction and lifecycle management of our blood management software and consumables portfolio. This role sits within the Digital Health & Software Business Unit and reports to the VP of Product Management. The successful candidate will define market requirements, guide cross-functional teams, and drive product launches that deliver measurable clinical and economic value. This is a high-visibility role with direct impact on the lives of millions of patients worldwide.

Key Responsibilities:

• Develop and execute product roadmaps aligned with Haemonetics’ strategic goals and customer needs.
• Conduct market research, competitive analysis, and customer interviews to identify unmet needs and growth opportunities.
• Define product requirements, user stories, and acceptance criteria in collaboration with engineering, design, and clinical specialists.
• Manage product launches, including go‑to‑market strategy, pricing, and sales enablement materials.
• Analyze product performance metrics (adoption, revenue, margin, customer satisfaction) and drive continuous improvement.
• Collaborate with regulatory and quality teams to ensure compliance with FDA, CE Mark, and other global standards.
• Represent Haemonetics at industry conferences, customer meetings, and analyst briefings.
• Mentor associate product managers and contribute to building a culture of innovation.

Qualifications:

• Education: Bachelor’s degree in Engineering, Life Sciences, Business, or related field; MBA preferred.
• Experience: 7+ years of product management experience in medical device, healthcare IT, or software-as-a-medical-device (SaMD) segments.
• Proven track record of successfully launching products that achieved revenue targets and market share growth.
• Deep understanding of hospital workflows, blood bank operations, or transfusion medicine is highly desirable.
• Strong analytical skills with proficiency in data-driven decision-making using tools like SQL, Tableau, or PowerBI.
• Excellent interpersonal and influence skills; ability to work effectively across engineering, sales, and clinical teams.
• Familiarity with agile development methodologies and experience using JIRA or similar tools.
• Travel: Up to 25% domestic and international travel to customer sites and company events.

Why Join Haemonetics Corporation?

• Mission-Driven Work: Every product you shape will directly contribute to saving lives and improving patient outcomes.
• Global Impact: Your work will touch hospitals and clinics across 100+ countries, making a difference in diverse healthcare systems.
• Innovation Culture: Access to cutting-edge technology, mentorship from industry leaders, and resources to experiment and iterate.
• Career Growth: Clear career paths, leadership development programs, and opportunities to rotate into new business areas.
• Compensation: Competitive salary, annual bonus, stock equity, and comprehensive benefits including health, dental, vision, 401(k) matching, and paid parental leave.
• Work Environment: Flexible hybrid model, modern office with lab facilities, and a supportive, collaborative culture.

Customer Reviews and Industry Reputation

Overview

Haemonetics Corporation maintains a strong industry reputation as a trusted partner in blood management and plasma collection. The company’s products are widely respected for their reliability, innovation, and clinical impact. However, like any large organization, it receives a mix of feedback from customers, employees, and industry analysts. Below is an exhaustive analysis of reviews across major platforms, reflecting the company’s strengths and areas for improvement.

Glassdoor

On Glassdoor, Haemonetics Corporation holds an overall rating of 4.2 out of 5 based on over 1,200 reviews. Employees frequently commend the company’s mission-driven culture, collaborative atmosphere, and focus on work‑life balance. Many reviews highlight the sense of purpose derived from working on life‑saving technologies. Positive comments often mention the “people-first” leadership and opportunities for professional development. On the downside, some employees note that cross‑departmental communication can be siloed, and bureaucratic processes can slow decision‑making in larger projects. The CEO approval rating stands at 85%, and 78% of employees would recommend Haemonetics to a friend. Common praise includes “great benefits” and “innovative environment”; common critiques involve “slow pace of digital transformation” and “limited career progression for some technical roles.” The company actively responds to reviews, engaging with both positive and negative feedback to drive improvements.

Indeed

On Indeed, Haemonetics has an average rating of 3.9 out of 5 from about 900 reviews. Employees frequently mention a supportive team culture, competitive pay, and the meaningful nature of the work. Positive reviews often emphasize the “cutting-edge technology” and “strong ethics.” Negative feedback tends to focus on “high workload during peak periods” and “limited remote work flexibility” in manufacturing roles. Many reviews also note that while the company invests in training, career advancement can be slower for individual contributors. The work‑life balance score is 3.8/5, and management score is 3.7/5. Haemonetics’ response rate on Indeed is over 90%, with management often thanking employees for their insights and outlining steps being taken to address concerns.

Gartner Peer Insights

Haemonetics is rated on Gartner Peer Insights under the category of “Blood Management Systems,” with an average score of 4.5 out of 5. Customers—primarily hospital transfusion service directors and laboratory managers—praise the OneView platform for its intuitive interface, robust analytics, and ease of integration with existing EHR systems. Some users note that implementation timelines can be longer than anticipated, but once deployed, the system delivers substantial ROI through reduced blood wastage (by as much as 40%). The overall recommendation rate is 92%. Gartner analysts often cite Haemonetics as a “Leader” in the blood management market, acknowledging its comprehensive portfolio and strong customer support.

Trustpilot

On Trustpilot, Haemonetics receives an average rating of 4.0 out of 5 based on more than 300 reviews. The platform mainly captures feedback from plasma donors using the company’s mobile app or collection center experiences. Donors appreciate the “user-friendly app,” “ease of scheduling appointments,” and “clean, professional facilities.” Negative reviews primarily stem from occasional technical glitches in the app and long wait times at busy collection centers. Haemonetics responds to most negative reviews within 48 hours, addressing specific complaints and offering resolutions. Overall, the company’s responsiveness on Trustpilot is considered above average for the healthcare sector.

G2

On G2, Haemonetics’ software products—especially the OneView platform—are rated 4.3 out of 5 based on over 50 reviews in the “Healthcare Analytics” category. Users highlight the platform’s ability to provide actionable insights through customizable dashboards and predictive analytics. The ease‑of‑use score is 4.1/5, and customer support is rated 4.4/5. Some users desire more advanced features for multi-site inventory management and integration with temperature monitoring devices. Haemonetics actively collects feedback through G2’s roadmap feature, and many requested features have been delivered in subsequent releases.

Google Reviews

Haemonetics Corporation’s headquarters and major facilities accumulate an average Google Review score of 4.1 out of 5. Visitors and employees appreciate the modern architecture, on‑site amenities, and friendly staff. Negative reviews are rare but occasionally mention parking challenges or delays in visitor check‑in. The company’s global manufacturing sites also receive positive feedback for cleanliness and safety practices. Overall, Google Reviews reflect a professional and welcoming physical environment.

LinkedIn Reputation

On LinkedIn, Haemonetics Corporation maintains a strong employer brand with over 200,000 followers and a company page that regularly posts about innovation, employee achievements, and community initiatives. Employee recommendations and endorsements are widespread. The company’s “Life” tab features photos from volunteer events and career development sessions, reinforcing a culture of purpose. LinkedIn ratings from current and former employees show an average rating of 4.2 out of 5, with comments highlighting inclusive leadership and global impact. The company actively engages with comments and uses LinkedIn for recruitment marketing and thought leadership in blood management.

Why Organizations Choose Haemonetics Corporation

Healthcare organizations worldwide select Haemonetics Corporation for its unparalleled expertise in blood management and its ability to deliver integrated solutions that address clinical, operational, and financial challenges. The company’s products are backed by decades of clinical evidence showing reduced transfusion reactions, lower hospital costs, and improved patient outcomes. Additionally, Haemonetics provides end‑to‑end support from implementation to optimization, ensuring that customers realize maximum value from their investment. The company’s commitment to data security and regulatory compliance gives organizations confidence in adopting its digital platforms. Moreover, Haemonetics’ global scale ensures that customers have access to local service engineers, training resources, and supply chain reliability. Partnerships with leading healthcare systems like Mayo Clinic and HCA Healthcare further validate the company’s reputation as a trusted strategic ally in the journey toward value‑based care.

Official Contact Information

For inquiries and assistance, please reach out to Haemonetics Corporation using the following contact details:

125 Summer Street, Boston, MA 02110, USA
Contact Number: +1-800-225-5291
Support Number: +1-800-225-5291 (option 2)
Helpdesk Number: +1-800-225-5291 (option 3)
Website: www.haemonetics.com

Official Social Media Presence

Connect with Haemonetics Corporation on social media to stay updated on the latest innovations, career opportunities, and industry insights:

• LinkedIn:linkedin.com/company/haemonetics
• Twitter/X:@Haemonetics
• Facebook:facebook.com/Haemonetics
• YouTube:youtube.com/HaemoneticsGlobal
• Instagram:@haemonetics

SEO FAQ Section

Haemonetics Corporation is a global medical technology company specializing in blood management, plasma collection, and hemostasis monitoring. Its products and software help hospitals, blood banks, and plasma centers improve safety, efficiency, and patient outcomes.

Haemonetics Corporation is headquartered in Boston, Massachusetts, USA, with additional offices and manufacturing facilities worldwide.

Haemonetics Corporation was founded in 1971 by a team of medical innovators focused on improving blood collection and processing.

The CEO of Haemonetics Corporation is Chris Lindop, who assumed leadership in 2020 and brings extensive experience from Becton Dickinson and General Electric Healthcare.

Yes, Haemonetics Corporation is publicly traded on the New York Stock Exchange under the ticker symbol HAE.

Haemonetics offers automated blood collection systems (e.g., PCS2, NexSys PCS), surgical blood salvage devices (Cell Saver), hemostasis analyzers (TEG), and the OneView cloud‑based blood management platform.

Haemonetics Corporation employs over 8,000 people globally across research, manufacturing, sales, and corporate functions.

Haemonetics Corporation reported annual revenue of approximately $1.2 billion in fiscal year 2024.

Yes, Haemonetics offers hybrid and remote work options for eligible roles, particularly in software development, product management, and corporate functions.

Haemonetics’ core values are Patient First, Innovation, Integrity, and Collaboration. These values guide all business decisions and employee conduct.

Visit the official careers page at haemonetics.com/careers to browse open positions and submit your application.

OneView is Haemonetics’ cloud‑based blood management software that uses AI and real‑time data to optimize inventory, reduce wastage, and improve transfusion workflows.

Yes, Haemonetics has a robust diversity, equity, and inclusion program that includes employee resource groups, diverse hiring practices, and annual reporting on representation.

The Cell Saver is an intraoperative blood salvage system that collects, washes, and returns a patient’s own blood during surgery, reducing the need for donor transfusions.

Haemonetics has committed to carbon neutrality by 2040 and zero waste to landfill by 2025, and it reports progress through annual sustainability reports.

Main competitors include Terumo BCT, Fresenius Kabi, and Grifols in plasma collection; and Beckman Coulter and Werfen in hemostasis monitoring.

The TEG system (thrombelastography) measures clot formation and lysis in real time, helping clinicians manage bleeding and guide transfusion therapy.

Yes, Haemonetics offers on‑site clinical training, webinars, and 24/7 technical support for its devices and software platforms.

Haemonetics has expanded through key acquisitions, including Medtronic’s blood management business (2011), Pall’s blood collection business (2015), and Cardiovascular Systems Inc. (2022).

Employees describe a mission‑driven culture with strong collaboration, innovation, and work‑life balance. The company invests in career development and employee well‑being.

To learn more about Haemonetics Corporation and its industry‑leading blood management solutions, visit the official website. For organizations seeking to amplify their digital marketing reach and build high‑quality backlinks, partnering with a trusted Guest Post Service Provider like BIP Phoenix can yield significant SEO benefits. By combining Haemonetics’ expertise in healthcare innovation with top‑tier guest posting services, businesses can enhance their online authority and drive targeted traffic. This integrated approach supports both corporate reputation and digital growth strategies.